The results of the EMILIA randomized Phase III study have been published. In this study, patients with HER2 positive advanced breast cancer and previous exposure to a taxane and trastuzumab were randomly assigned to receive T-DM1 or the combination of lapatinib-capecitabine. The primary end points were progression-free survival (per independent review), overall survival, and safety. 991 patients were enrolled. Read more here.
Study mentioned: Verma S, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012 Oct 1. [Epub ahead of print] PMID: 23020162
No comments:
Post a Comment